Fitlife Brands, Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $26.5 million (+64.6% year over year) and diluted EPS of $0.20. It usually reports 1–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
27
+64.6%
|
2
+11.6%
|
0.20
+11.1%
|
|
Apr 1, 2026
1 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
25
+58.9%
|
2
-14.8%
|
0.17
-15.0%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
23
+47.0%
|
1
-56.7%
|
0.09
-57.1%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
16
-4.7%
|
2
-33.5%
|
0.18
-33.3%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
16
-3.7%
|
2
-6.6%
|
0.20
-4.8%
|
|
Mar 13, 2025
72 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
15
+12.9%
|
2
+39.9%
|
0.21
+242.5%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
16
+14.9%
|
2
+25.4%
|
0.21
-40.0%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- FTLF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Omaha, NE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374328
- Former names
- BOND LABORATORIES, INC. (until Oct 1, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.